In those who are overweight or obese, metformin may lower their risk of developing long-term COVID.

Published Date: 22 Jun 2023

According to data from the COVID-OUT trial, metformin use may reduce a person's risk of long-term COVID by more than 50% compared to placebo therapy. The trial's findings also shed light on the apparent lack of benefit from ivermectin and fluvoxamine.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot